(209 days)
FOR TOPICAL DERMATOLOGICAL USE ONLY
Description Rx Product:
Under the supervision of a healthcare professional, Sinclair Wound and Skin Emulsion is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis, atopic dermatitis and allergic contact dermatitis. Sinclair Wound and Skin Emulsion may be used to relieve the pain of first and second degree burns. Sinclair Wound and Skin Emulsion helps to relieve dry waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process.
Description OTC Product:
Sinclair Wound and Skin Emulsion helps to nourish skin and relieve the burning and itching associated with many common types of skin irritation. Sinclair Wound and Skin Emulsion may also be used to soothe minor burns, including sunburn.
Sinclair Wound and Skin Emulsion is a non sterile viscous emulsion / gel formulation, which is presented for both Prescription (requires physician diagnosis of disease state) and over-thecounter (OTC) use.
Here's a breakdown of the acceptance criteria and the study information for the SINCLAIR WOUND AND SKIN EMULSION™ based on the provided document:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Safety | Functional and performance testing has been conducted to assess the safety. All results are satisfactory. |
| Effectiveness | Functional and performance testing has been conducted to assess the effectiveness. All results are satisfactory. |
| Substantial Equivalence | The device is substantially equivalent to legally marketed predicate devices: Biafene Wound Dressing Emulsion (K964240) and Carrasyn® Hydrogel Wound Dressing (K961758) / RadiaCare Gel Hydrogel Wound Dressing. |
2. Sample Size Used for the Test Set and Data Provenance
The provided document does not specify a sample size for a test set. It mentions "Functional and performance testing," but does not detail the methodology, sample sizes, or provenance of the data (e.g., country of origin, retrospective or prospective) for these tests.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
The provided document does not mention or describe the use of experts to establish ground truth for any test set.
4. Adjudication Method for the Test Set
The provided document does not mention or describe any adjudication method for a test set.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
A multi-reader multi-case (MRMC) comparative effectiveness study was not performed or reported in the provided document. The submission focuses on demonstrating substantial equivalence to predicate devices through functional and performance testing, not direct comparison of human readers with and without AI assistance.
6. Standalone (Algorithm Only) Performance Study
A standalone performance study of an algorithm was not performed or reported in the provided document. This device is a wound and skin emulsion, not an AI algorithm. The functional and performance testing mentioned refers to the physical and chemical properties and likely biocompability of the emulsion itself.
7. Type of Ground Truth Used
The concept of "ground truth" as typically used in AI/diagnostic device studies (e.g., expert consensus, pathology, outcomes data) is not directly applicable or discussed in this submission. The "ground truth" for this device's performance would likely be established through standardized methods for assessing biocompatibility, stability, physical properties (e.g., viscosity, pH), and potentially in-vitro or in-vivo wound healing models, though these specifics are not detailed in the document. The substantial equivalence relies on comparison to predicate devices.
8. Sample Size for the Training Set
A "training set" is relevant for machine learning algorithms. Since this device is a topical emulsion and not an AI/ML algorithm, the concept of a training set does not apply to this submission.
9. How the Ground Truth for the Training Set was Established
As the concept of a training set does not apply, how its ground truth was established is not applicable to this submission.
{0}------------------------------------------------
Attachment 6
510(kg){"g":"g":"g":"2003
KOZ4367
December 30, 2002
1. Submission Applicant & Correspondent:
Sinclair Pharmaceuticals, Ltd. Name: Borough Road Address: Godalming Surrey GU7 2AB United Kingdom
1-972-939-2442 Phone No .: Michael Killeen Contact Person:
| 2. Name of Device: | SINCLAIR WOUND AND SKIN EMULSIONTM |
|---|---|
| Trade/Proprietary/Model Name: | SINCLAIR WOUND AND SKIN EMULSIONTM |
| Common or Usual Name: | Dressing, Wound & Burn, Hydrogel w/Drug orBiologic |
| Classification Names: | Dressing, Wound & Burn, Hydrogel w/Drug orBiologic |
3. Devices to Which New Device is Substantially Equivalent:
- Biafene Wound Dressing Emulsion (Radiodermatitis Emulsion) in 510(k) K964240, from ● Medix Pharmaceuticals Americas Inc. and
- Carrasyn® Hydrogel Wound Dressing 510(k) K961758, which is also marketed ● under the name RadiaCare Gel Hydrogel Wound Dressing.
4. Device Description:
D
Sinclair Wound and Skin Emulsion is a non sterile viscous emulsion / gel formulation, which is presented for both Prescription (requires physician diagnosis of disease state) and over-thecounter (OTC) use.
5. Intended Use of the Device:
The prescription product requires a physician to diagnose the disease state, while the OTC product is indicated for general symptoms such as burning and itching in minor skin irritations and minor burns. This formulation, when applied to the burn, injured tissue or skin, forms a protective barrier that helps to keep the wound moist.
6. Summary of Technological Characteristics of the Device Compared to the Predicate Devices:
All products referenced are non sterile emulsion/gel types that are applied topically to relieve the symptoms of various dermatoses.
7. Tests and Conclusions:
Functional and performance testing has been conducted to assess the safety and effectiveness of SINCLAIR WOUND AND SKIN EMULSION ™ and all results are satisfactory.
Sinclair Pharmaceuticals Ltd 510(k) Submission for Sinclair Wound and Skin Emulsion
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the logo is an abstract symbol that resembles an eagle or a bird in flight.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 2 8 2003
Mr. Michael Killeen Executive Director Sinclair Pharmaceuticals, Ltd. Borough Road Godalming, Surrey United Kingdom GU7 2AB
Re: K024367
Trade/Device Name: Sinclair Wound and Skin Emulsion™ Regulation Name: Hydrogel wound dressing and burn dressing Regulatory Class: Unclassified Product Code: MGQ Dated: April 25, 2003 Received: May 6, 2003
Dear Mr. Killeen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.'
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
Page 2 - Mr. Michael Killeen
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
iriam C. Provost
Colia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
KOZY367
| Attachment 3 - Indications for Use Statement | |
|---|---|
| 510(k) Number | NA |
| Device Name | SINCLAIR WOUND AND SKIN EMULSION ™ |
| Indications for Use | FOR TOPICAL DERMATOLOGICAL USE ONLY |
| Description Rx Product:Under the supervision of a healthcare professional, Sinclair Wound and SkinEmulsion is indicated to manage and relieve the burning, itching and painexperienced with various types of dermatoses, including radiationdermatitis, atopic dermatitis and allergic contact dermatitis. Sinclair Woundand Skin Emulsion may be used to relieve the pain of first and seconddegree burns. Sinclair Wound and Skin Emulsion helps to relieve dry waxyskin by maintaining a moist wound & skin environment, which is beneficialto the healing process. | |
| Directions For Use (Rx and OTC):Apply Sinclair Wound and Skin Emulsion to the affected skin areas 3times per day (or as needed), and massage gently into the skin. If the skin isbroken, cover Sinclair Wound and Skin Emulsion with a dressing ofchoice. | |
| Description OTC Product:Sinclair Wound and Skin Emulsion helps to nourish skin and relieve theburning and itching associated with many common types of skin irritation.Sinclair Wound and Skin Emulsion may also be used to soothe minor burns,including sunburn. | |
| PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IFNEEDED | |
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
| Miriam C. Provost(Division Sign-Off)Division of General, Restorativeand Neurological Devices | |
| Prescription Use(per 21 CFR 801.109) | |
| 510(k) Number | K0 24367 |
| Over-The Counter Use |
:
N/A